185 related articles for article (PubMed ID: 16636137)
1. A boronic-chalcone derivative exhibits potent anticancer activity through inhibition of the proteasome.
Achanta G; Modzelewska A; Feng L; Khan SR; Huang P
Mol Pharmacol; 2006 Jul; 70(1):426-33. PubMed ID: 16636137
[TBL] [Abstract][Full Text] [Related]
2. Novel p-Functionalized Chromen-4-on-3-yl Chalcones Bearing Astonishing Boronic Acid Moiety as MDM2 Inhibitor: Synthesis, Cytotoxic Evaluation and Simulation Studies.
Bhatia RK; Singh L; Garg R; Kaur M; Yadav M; Madan J; Kancherla S; Pissurlenkar RRS; Coutinho EC
Med Chem; 2020; 16(2):212-228. PubMed ID: 31146672
[TBL] [Abstract][Full Text] [Related]
3. Enhanced cytotoxicity of prenylated chalcone against tumour cells via disruption of the p53-MDM2 interaction.
Leão M; Soares J; Gomes S; Raimundo L; Ramos H; Bessa C; Queiroz G; Domingos S; Pinto M; Inga A; Cidade H; Saraiva L
Life Sci; 2015 Dec; 142():60-5. PubMed ID: 26475964
[TBL] [Abstract][Full Text] [Related]
4. Anticancer activities of novel chalcone and bis-chalcone derivatives.
Modzelewska A; Pettit C; Achanta G; Davidson NE; Huang P; Khan SR
Bioorg Med Chem; 2006 May; 14(10):3491-5. PubMed ID: 16434201
[TBL] [Abstract][Full Text] [Related]
5. A tryptophanol-derived oxazolopiperidone lactam is cytotoxic against tumors via inhibition of p53 interaction with murine double minute proteins.
Soares J; Raimundo L; Pereira NA; dos Santos DJ; Pérez M; Queiroz G; Leão M; Santos MM; Saraiva L
Pharmacol Res; 2015; 95-96():42-52. PubMed ID: 25814188
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, and
Alimujiang Y; Maimaiti A; Ablise M; Yang Z; Liu Z; Wang Y; Mutalipu Z; Yan T
Anticancer Agents Med Chem; 2024; 24(6):423-435. PubMed ID: 38204258
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of curcumin derivatives modified with α-amino boronic acid as proteasome inhibitors.
Zhang W; Bai H; Han L; Zhang H; Xu B; Cui J; Wang X; Ge Z; Li R
Bioorg Med Chem Lett; 2018 Aug; 28(14):2459-2464. PubMed ID: 29886021
[TBL] [Abstract][Full Text] [Related]
8. Chalcone-based small-molecule inhibitors attenuate malignant phenotype via targeting deubiquitinating enzymes.
Issaenko OA; Amerik AY
Cell Cycle; 2012 May; 11(9):1804-17. PubMed ID: 22510564
[TBL] [Abstract][Full Text] [Related]
9. Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175.
Hayward RL; Schornagel QC; Tente R; Macpherson JS; Aird RE; Guichard S; Habtemariam A; Sadler P; Jodrell DI
Cancer Chemother Pharmacol; 2005 Jun; 55(6):577-83. PubMed ID: 15726367
[TBL] [Abstract][Full Text] [Related]
10. p53-dependent and -independent mechanisms are involved in (E)-1-(2-hydroxyphenyl)-3-(2-methoxynaphthalen-1-yl)prop-2-en-1-one (HMP)-induced apoptosis in HCT116 colon cancer cells.
Shin SY; Ahn S; Koh D; Lim Y
Biochem Biophys Res Commun; 2016 Oct; 479(4):913-919. PubMed ID: 27641669
[TBL] [Abstract][Full Text] [Related]
11. Trans-4-lodo,4'-boranyl-chalcone induces antitumor activity against malignant glioma cell lines in vitro and in vivo.
Sasayama T; Tanaka K; Mizukawa K; Kawamura A; Kondoh T; Hosoda K; Kohmura E
J Neurooncol; 2007 Nov; 85(2):123-32. PubMed ID: 17530176
[TBL] [Abstract][Full Text] [Related]
12. Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.
Scarbaci K; Troiano V; Ettari R; Pinto A; Micale N; Di Giovanni C; Cerchia C; Schirmeister T; Novellino E; Lavecchia A; Zappalà M; Grasso S
ChemMedChem; 2014 Aug; 9(8):1801-16. PubMed ID: 24891205
[TBL] [Abstract][Full Text] [Related]
13. Oxazoloisoindolinones with in vitro antitumor activity selectively activate a p53-pathway through potential inhibition of the p53-MDM2 interaction.
Soares J; Pereira NA; Monteiro Â; Leão M; Bessa C; Dos Santos DJ; Raimundo L; Queiroz G; Bisio A; Inga A; Pereira C; Santos MM; Saraiva L
Eur J Pharm Sci; 2015 Jan; 66():138-47. PubMed ID: 25312347
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents.
Kumar SK; Hager E; Pettit C; Gurulingappa H; Davidson NE; Khan SR
J Med Chem; 2003 Jul; 46(14):2813-5. PubMed ID: 12825923
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors.
Ge Y; Li A; Wu J; Feng H; Wang L; Liu H; Xu Y; Xu Q; Zhao L; Li Y
Eur J Med Chem; 2017 Mar; 128():180-191. PubMed ID: 28182990
[TBL] [Abstract][Full Text] [Related]
16. Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells.
Nencioni A; Wille L; Dal Bello G; Boy D; Cirmena G; Wesselborg S; Belka C; Brossart P; Patrone F; Ballestrero A
Clin Cancer Res; 2005 Jun; 11(11):4259-65. PubMed ID: 15930365
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation.
Seo SK; Jin HO; Woo SH; Kim YS; An S; Lee JH; Hong SI; Lee KH; Choe TB; Park IC
J Thorac Oncol; 2011 Aug; 6(8):1313-9. PubMed ID: 21642861
[TBL] [Abstract][Full Text] [Related]
18. Activation of p53-dependent apoptosis by acute ablation of glycogen synthase kinase-3beta in colorectal cancer cells.
Ghosh JC; Altieri DC
Clin Cancer Res; 2005 Jun; 11(12):4580-8. PubMed ID: 15958644
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.
Ling YH; Liebes L; Jiang JD; Holland JF; Elliott PJ; Adams J; Muggia FM; Perez-Soler R
Clin Cancer Res; 2003 Mar; 9(3):1145-54. PubMed ID: 12631620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
